Atossa Therapeutics Inc (ATOS)

08:30 AM

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women - PR Newswire

08:30 AM

May 04, 2026

Atossa Genetics stock surges after FDA rare disease designation By Investing.com - Investing.com South Africa

May 04, 2026

May 04, 2026

Atossa Genetics stock surges after FDA rare disease designation - Investing.com

May 04, 2026

May 04, 2026

Atossa Therapeutics (ATOS) Secures FDA Designation for Pediatric Treatment - GuruFocus

May 04, 2026

May 04, 2026

Atossa gets rare pediatric disease tag for endoxifen in MAS By Investing.com - Investing.com South Africa

May 04, 2026

May 04, 2026

FDA awards Atossa Therapeutics rare pediatric designation for Z-endoxifen milestone - Traders Union

May 04, 2026

May 04, 2026

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome - PR Newswire

May 04, 2026

May 04, 2026

ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill

May 04, 2026

May 01, 2026

ATOS Should I Buy - Intellectia AI

May 01, 2026

Apr 28, 2026

Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN

Apr 28, 2026

Apr 26, 2026

ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN

Apr 26, 2026

Apr 25, 2026

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Aktiellt

Apr 25, 2026

Apr 24, 2026

Atossa Therapeutics joins industry leaders at LSINW2026 to advance cell therapy innovation momentum - Traders Union

Apr 24, 2026

Apr 17, 2026

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Apr 17, 2026

Apr 17, 2026

ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill

Apr 17, 2026

Apr 16, 2026

Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights - TipRanks

Apr 16, 2026

Apr 16, 2026

Atossa Therapeutics reaches settlement in Endoxifen patent dispute By Investing.com - Investing.com South Africa

Apr 16, 2026

Apr 16, 2026

Atossa Therapeutics reaches settlement in Endoxifen patent dispute - Investing.com

Apr 16, 2026

Apr 16, 2026

Atossa Therapeutics (NASDAQ: ATOS) settles key Endoxifen patent fight - Stock Titan

Apr 16, 2026

Apr 16, 2026

Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62 - MSN

Apr 16, 2026

Apr 14, 2026

Atossa Therapeutics advances endoxifen as new option for DMD management - Traders Union

Apr 14, 2026

Apr 10, 2026

ATOS: Ascendiant Capital Lowers Price Target Despite Maintaining 'Buy' Rating | ATOS Stock News - GuruFocus

Apr 10, 2026

Apr 09, 2026

Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026 - Traders Union

Apr 09, 2026

Apr 08, 2026

Atossa Therapeutics: A 2026 Regulatory Milestone in Sight - AD HOC NEWS

Apr 08, 2026

Apr 03, 2026

ATOS Stock Eyes Fresh Highs Amid Strong Buying Pressure - Cổng thông tin điện tử Tỉnh Sơn La

Apr 03, 2026

Apr 01, 2026

Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation - AD HOC NEWS

Apr 01, 2026

Mar 31, 2026

Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan

Mar 31, 2026

Mar 31, 2026

Atossa Therapeutics announces issuance of U.S. patent - MSN

Mar 31, 2026

Mar 30, 2026

Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years - Stock Titan

Mar 30, 2026

Mar 30, 2026

[ARS] ATOSSA THERAPEUTICS, INC. SEC Filing - Stock Titan

Mar 30, 2026

Mar 30, 2026

[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan

Mar 30, 2026

Mar 30, 2026

NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation - Traders Union

Mar 30, 2026

Mar 29, 2026

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits

Mar 29, 2026

Mar 28, 2026

Entry Recap: Is Atossa Therapeutics Inc a speculative investment2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn

Mar 28, 2026

Mar 28, 2026

Risk Off: Is Atossa Therapeutics Inc stock heavily shorted2026 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

ATOS Price Today: Atossa Therapeutics, Inc. Stock Price, Quote & Chart - MEXC

Mar 27, 2026

Mar 27, 2026

H.C. Wainwright raises Atossa Genetics price target to $25 from $7 - Investing.com

Mar 27, 2026

Mar 26, 2026

ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus

Mar 26, 2026

Mar 26, 2026

Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus

Mar 26, 2026

Mar 26, 2026

Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn

Mar 26, 2026

Mar 26, 2026

Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart

Mar 26, 2026

Mar 26, 2026

Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart

Mar 26, 2026

Mar 26, 2026

Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus

Mar 26, 2026

Mar 25, 2026

Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS

Mar 25, 2026